D. B. Volkin

This study develops and compares an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced in two cell lines, showing similar immunogenicity despite differences in glycoforms.

This paper evaluates the stability and immunogenicity of a SARS-CoV-2 RBD VLP vaccine candidate formulated with different adjuvants and finds that AP and AH adjuvants provide comparable immunogenicity to AV, with AP showing higher neutralizing titers.

The paper correlates physicochemical properties of an rAAV vaccine candidate with its biological potency, showing links between physical stability, transduction efficiency, and immunogenicity.

This paper describes a ferritin-based nanoparticle vaccine, DCFHP-alum, that induces strong, long-lasting neutralizing antibodies against SARS-CoV-2 variants in non-human primates.

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

The paper engineers subunit antigens to improve vaccine manufacturing by reducing variants and enabling single-process production of a trivalent rotavirus vaccine.